OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Paulson on Molecular Testing in Oncology

January 24th 2020

R. Steven Paulson, MD, discusses molecular testing in oncology.

Dr. Yasenchak on Brentuximb Vedotin Plus Nivolumab in Hodgkin Lymphoma

January 24th 2020

Christopher A. Yasenchak, MD, discusses brentuximab vedotin (Adcetris) plus nivolumab (Opdivo) in patients with Hodgkin lymphoma.

Dr. Brammer on the Transformation of Stem Cell Transplant in ALL

January 24th 2020

Jonathan E. Brammer, MD, discusses the progression of transplant in acute lymphoblastic leukemia.

Dr. Chittoor on Targetable Mutations and Respective Treatments in NSCLC

January 24th 2020

Sreeni Chittoor, MD, FACP, discusses targetable mutations and respective treatment options for patients with metastatic non–small cell lung cancer.

Dr. Levy on Positive and Negative Biomarkers for Immunotherapy in Lung Cancer

January 24th 2020

Benjamin P. Levy, MD, discusses biomarkers for immunotherapy in lung cancer.

Dr. Cline on Data With PARP Inhibitors in Pancreatic Cancer

January 23rd 2020

Mika Cline, MD, discusses data with PARP inhibitors in patients with BRCA1/2 mutated pancreatic cancer.

Dr. Voorhees on Updated Depth of Response in GRIFFIN Trial in Multiple Myeloma

January 23rd 2020

Peter Voorhees, MD, discusses the updated depth of response data that were reported in the GRIFFIN trial of patients with multiple myeloma.

Dr. Hegazi on Nutrition-Related Toxicities in Oncology

January 23rd 2020

Refaat Hegazi, MD, PhD, MPH, discusses nutrition-related toxicities in oncology.

Dr. Vusirikala on the Role of MRD in ALL

January 23rd 2020

Madhuri Vusirikala, MD, discusses the role of minimal residual disease in acute lymphoblastic leukemia.

Dr. Heath on Remaining Challenges in Nonmetastatic CRPC

January 23rd 2020

Elisabeth I. Heath, MD, FACP, discusses a remaining challenge in nonmetastatic castration-resistant prostate cancer.

Dr. Backes on Toxicity Considerations With PARP Inhibitors in Ovarian Cancer

January 23rd 2020

Floor J. Backes, MD, discusses toxicity considerations with PARP inhibitors in ovarian cancer.

Dr. Wong on Antibody-Drug Conjugate Research in Multiple Myeloma

January 23rd 2020

Sandy Wong, MD, discusses the ongoing research of antibody-drug conjugates in multiple myeloma.

Dr. Gibbs on Testing for p16 and p21 in Osteosarcoma

January 23rd 2020

C. Parker Gibbs Jr, MD, discusses how to test for p16 and p21 in patients with osteosarcoma.

Dr. Abou-Alfa on Ramucirumab as Second-Line Therapy for Hepatocellular Carcinoma

January 23rd 2020

Ghassan K. Abou-Alfa, MD, discusses the role of ramucirumab in the treatment of patients with hepatocellular carcinoma in the second-line setting.

Dr. Ramakrishnan on Benefit of CAR T-Cell Therapy in MCL

January 22nd 2020

Praveen Ramakrishnan, MD, discusses the benefit of CAR T-cell therapy in patients with mantle cell lymphoma.

Dr. Sharman on the Design of the ELEVATE-TN Trial in CLL

January 22nd 2020

Jeff Sharman, MD, discusses the design of the phase III ELEVATE-TN trial in patients with previously untreated chronic lymphocytic leukemia.

Dr. Zhu on Mitigating Toxicities of Elective Nodal Irradiation in Breast Cancer

January 22nd 2020

He James Zhu, MD, PhD, discusses potential strategies to mitigate the toxicities of elective nodal irradiation in breast cancer.

Dr. Herbst on Combination of Nivolumab and Ipilimumab in Patients With NSCLC

January 22nd 2020

Roy S. Herbst, MD, PhD, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with advanced non–small-cell lung cancer (NSCLC).

Dr. Norden on Cost and Effectiveness of Genomic Testing

January 22nd 2020

Andrew Norden, MD, MPH, MBA, chief medical officer, Cota, discusses concerns surrounding cost and efficacy of molecular testing.

Dr. Anderson on Recent FDA Approvals in Multiple Myeloma

January 22nd 2020

Larry Anderson, MD, PhD, discusses recent FDA approvals in multiple myeloma.